The Impact of Dabigatran and Rivaroxaban on Variation of Platelet Activation Biomarkers and DRT Following Percutaneous Left Atrial Appendage Closure.

Li, Xiaoye; Zhang, Xiaochun; Jin, Qinchun; Li, Yanli; Zhou, Daxin; Lv, Qianzhou; Ge, Junbo

Li, Xiaoye; Zhang, Xiaochun; Jin, Qinchun; Li, Yanli; Zhou, Daxin; Lv, Qianzhou; Ge, Junbo.

Afiliação

Li X; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhang X; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jin Q; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Li Y; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhou D; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Lv Q; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Ge J; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.

Front Pharmacol ; 12: 723905, 2021.

Article em En | MEDLINE | ID: mdl-34603033

Palavras-chave

P-selectin; device-related thrombosis; direct oral anticoagulants; percutaneous left atrial appendage closure; platelet activation biomarkers; thrombin receptoractivating peptideinduced platelet aggregation; thrombinantithrombin complex; von Willebrand disease

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google